Takeda R&D chief Andy Plump to retire in June 2027, will stay on board through 2027
Takeda announced that Andy Plump, who has led the company's research and development since 2015, will retire in June 2027.
Plump will remain president of R&D until a successor is appointed and will assist with the transition, after which he will continue serving on Takeda's board until the shareholder meeting in June 2027.
The company highlighted his role in modernizing Takeda's R&D, expanding partnerships with biotech firms, pursuing opportunities in China, and building a rare-disease business following the 2019 Shire acquisition.
CEO Julie Kim said his work created a lasting foundation for future patient-focused innovation.
This writeup was produced by pharmadog from original reporting by BioPharma Dive.
Original headline: “Andy Plump, architect of Takeda’s R&D overhaul, to retire next year”
read at BioPharma Dive ↗
comments(0)
5-min edit window · permanent after that